肥胖烧伤患者静脉血栓栓塞预防的单中心经验
本研究回顾性分析43例肥胖烧伤患者,评估依诺肝素40mg每日两次能否达到预防性抗Xa峰值水平。固定剂量方案不足,需按抗Xa水平调整剂量。
要点
- 未达标者更多为男性且平均体重更高。
- 需按抗Xa水平调整剂量以改善预防效果。
核心结论
- 固定40mg每日两次依诺肝素方案在肥胖烧伤患者中不足以达到目标预防性抗Xa峰值水平。
- 按抗Xa水平调整依诺肝素剂量以降低静脉血栓栓塞率需进一步评估。
研究设计与样本
- 纳入标准:年龄≥18岁,体重≥100 kg或BMI≥30 kg/m2,接受依诺肝素40mg每日两次预防静脉血栓栓塞,且至少连续3剂并监测抗Xa峰值。
主要发现
- 未达标者更多为男性(P<0.05)。
- 未达标者平均体重更高(129±24 kg vs 110±16 kg,P<0.05)。
关键数值与推荐
- 目标预防性抗Xa峰值水平为0.2-0.5 IU/ml。
- 依诺肝素初始剂量为40mg每日两次。
临床怎么用
- 肥胖烧伤患者使用固定40mg每日两次依诺肝素时,应监测抗Xa峰值水平。
- 未达目标抗Xa水平者应考虑剂量调整,并可能需多次调整。
局限性
- 回顾性单中心设计。
- 样本量较小(43例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Burn injured patients are at high risk of thromboembolic complications. Morbid obesity further increases this risk. Our objective was to evaluate the efficacy of enoxaparin dosed 40 mg twice daily in achieving prophylactic plasma anti-Xa levels in obese burn patients. A retrospective chart review from November 2018 until September 2019 identified patients who were either ≥100 kg or had a body mass index ≥30 kg/m2 and initiated on enoxaparin 40 mg twice daily for venous thromboembolism prophylaxis. Patients were ≥18 yr of age and received ≥3 sequential doses of enoxaparin with appropriately timed peak plasma anti-Xa levels to monitor efficacy. One hundred forty-eight patients were screened with 43 patients included for analysis. Forty-two percent of the patients did not reach target peak plasma anti-Xa levels (0.2-0.5 IU/ml) on enoxaparin 40 mg twice daily. Patients who did not meet prophylactic target levels were more likely to be male (P < 0.05) and have an increased mean body weight (129 ± 24 kg vs 110 ± 16 kg, P < 0.05). Thirteen out of 18 patients received dosage adjustments with subsequent anti-Xa levels available for follow-up assessment, of which an additional six patients required further dosage adjustment to meet prophylactic goals. Current utilization of a fixed 40 mg twice daily regimen of enoxaparin for venous thromboembolism (VTE) is inadequate to meet target prophylactic peak plasma anti-Xa levels in the obese burn patient population. Dose adjusting enoxaparin to target anti-Xa levels to reduce VTE rates in obese burn patients should be further evaluated.
引用
- McKinzie BP, Nizamani R, Jones S, et al. Single-center Experience with Venous Thromboembolism Prophylaxis for Obese Burn Patients. J Burn Care Res. 2021. PMID: 33674883. doi:10.1093/jbcr/irab039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。